(Reuters) - With priority review status, the U.S. Food and Drug
Administration will make its decision on whether to approve the
drug for the new use within six months, rather than the usual
10- to 12-month review period.
The agency grants priority review to products that are
considered to be potentially significant therapeutic
advancements over existing therapies.
Read more at Reuters.com Government Filings News
Administration will make its decision on whether to approve the
drug for the new use within six months, rather than the usual
10- to 12-month review period.
The agency grants priority review to products that are
considered to be potentially significant therapeutic
advancements over existing therapies.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment